What Vernalis does

Vernalis (R&D) Limited is a UK-based, revenue-generating contract research organization providing integrated drug discovery services to pharmaceutical and biotechnology companies. Operating from a single site at Granta Park, Cambridge, the company employs approximately 70 scientists organized across protein science, hit identification and assay, biophysics and structural biology, medicinal and computational chemistry, cell biology, and DMPK functions. Its core technical platform centers on fragment-based drug discovery (FBDD) and structure-based drug discovery (SBDD), augmented by DNA Encoded Library (DEL) capabilities (including proprietary PAC-FragmentDEL technology developed with parent company HitGen), proprietary Off-Rate Screening (ORS), in-house X-ray crystallography (over 7000 structures solved across 70+ targets), NMR (Bruker 600 MHz with QCI-F cryoprobe), and SPR (Biacore 8K and T200) platforms. The company operates a project-based fee-for-service commercial model, offering collaboration structures that range from long-term multi-target programs to short discrete pieces of work, with named enterprise clients including Servier, Genentech, Lundbeck, Pierre Fabre, and C4X Discovery.

Vernalis generates revenue exclusively through these custom contract research agreements; pricing is not publicly disclosed. Its go-to-market is direct enterprise engagement supplemented by scientific conference presence, peer-reviewed publications, and open-source software contributions (notably the Vernalis KNIME Nodes, one of the most downloaded KNIME community extensions in 2023). The company was originally founded as RiboTargets (pre-1998) and operates today as a wholly owned subsidiary of HitGen Inc., a Shanghai-listed (688222.SH) DEL technology company, gaining access to parent company DEL infrastructure while maintaining operational independence with its own leadership team in Cambridge. Recent strategic activity includes a drug discovery collaboration with C4X Discovery in inflammatory disease (April 2024) and entry into the €60M+ LIGAND-AI consortium led by Pfizer and the Structural Genomics Consortium (January 2026), positioning the company within the emerging AI-driven drug discovery ecosystem as a wet-lab data generation partner.

Name

Vernalis

Legal name

Vernalis (R&D) Limited

Website

https://vernalis.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

51–100 employees

Short description

Vernalis is a UK-based contract research organization that provides integrated fragment-based and structure-based drug discovery services to pharmaceutical and biotechnology clients from its Cambridge laboratories, operating as a wholly owned subsidiary of HitGen Inc.

Ownership category

akta.pro rank

Product category

Contract Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industries

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Drug discovery services
• Fragment-based drug discovery
• Structure-based drug discovery
• Medicinal chemistry services
• Preclinical drug development

Headquarters

HQ city

Winnersh

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Drug Discovery Contract Research Services: Vernalis generates revenue through fee-for-service drug discovery collaborations with pharmaceutical and biotechnology companies. Collaboration structures range from long-term multi-target projects to short discrete pieces of work. Services span the full drug discovery value chain from protein production through to pre-clinical candidate nomination.
2. Collaborative Research Agreements: Collaborative partnerships where work is funded by partners (e.g., C4X Discovery collaboration in inflammatory disease). Vernalis receives research funding while partners retain ownership of resulting intellectual property and have options to extend collaborations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Vernalis provides integrated, fee-for-service drug discovery collaborations to pharmaceutical and biotechnology companies, spanning the full value chain from protein production and hit identification (using fragment-based drug discovery, DNA-encoded library screening, and proprietary PAC-FragmentDEL) through structure-based lead optimisation, medicinal and flow chemistry, cell biology, and DMPK to pre-clinical candidate nomination. Services are delivered either as long-term multi-target programs or as short discrete pieces of work from its Cambridge, UK laboratories.

Product overview

Vernalis is a drug discovery services company offering an integrated platform of research services spanning from protein science through to candidate selection. The core offering consists of Protein Science Services (expression and purification), Hit ID and Assay services (including proprietary PAC-FragmentDEL Technology), Biophysics and Structural Biology, Chemistry Services (with Flow Chemistry and KNIME Nodes as key sub-products), Cell Biology, and DMPK services. These services are offered as a unified drug discovery platform enabling programs from gene to candidate, with collaboration structures varying from long-term multi-target projects to discrete pieces of work. Vernalis is a wholly owned subsidiary of HitGen Inc. and operates from Cambridge, UK.

Differentiator

Problem solved

Functional benefit

Products and services

• Protein Science Services Protein expression and purification services using multiple expression systems (E. coli, yeast, insect, mammalian cells) with ÄKTA chromatography systems. Includes protein quality control, site-specific labelling, and production of crystallographic-grade protein for structural studies. Supports Vernalis's internal and partner drug discovery programmes.
• Hit ID and Assay Services Hit identification services combining fragment-based drug discovery (FBDD), DNA Encoded Library (DEL) technology, medium-throughput biochemical screening (MTS), virtual screening, and knowledge-based approaches. Includes proprietary fragment libraries and PAC-FragmentDEL technology for partners seeking validated hit series.
• Biophysics and Structural Biology Services Biophysical and structural biology services including X-ray crystallography (in-house Bruker D8 source plus synchrotron access), NMR (Bruker 600 MHz with QCI-F cryoprobe), SPR (Biacore 8K and T200), ITC (Auto-iTC200), ASMS, and thermal shift assay. Has determined over 7,000 crystal structures for more than 70 protein targets.
• Chemistry Services Medicinal, synthetic, analytical, and computational chemistry services covering kinases, PPIs, GPCRs, and ion channels. Includes PROTAC and ADC design, flow chemistry, photochemistry, electrochemistry, and KNIME-based cheminformatics. Delivers lead optimisation and pre-clinical candidates for partners.
• Cell Biology Services Cell-based screening and pharmacology services including high-content imaging, flow cytometry, cell-based reporter assays (BiBiT), ELISA, high-throughput western blot, in-cell target engagement, RNAseq, and cytotoxicity. Includes a Class 2 containment laboratory for anti-infectives testing.
• DMPK Services In vitro ADME assays (kinetic solubility, PAMPA, Caco-2, MDCK, CYP inhibition, microsomal clearance, UGT clearance, hepatocyte clearance, metabolite identification), ex vivo bioanalysis, in vivo study design and management, bioanalysis of plasma and biofluids, tissue preparation, PK/PD evaluation, and pharmacokinetic reporting for partner programmes.
• PAC-FragmentDEL Technology Proprietary photoactivated capture fragment DNA-encoded library technology developed in collaboration with HitGen. Each library member consists of a fragment linked to a photoactivatable diazirine group; photoactivation covalently attaches binding fragments to the protein and hits are identified by PCR and Next-Generation Sequencing. Overcomes limitations of conventional fragment screening by requiring only small amounts of protein, running rapidly at low concentrations, and solubilising fragments via the DNA tag. Offered to partners as a differentiated hit identification capability.
• Flow Chemistry Services Flow chemistry services built around one of the largest Syrris Asia flow chemistry systems in the world. Supports automated synthesis, preparation of large compound libraries in 96-well plate format, crude reaction mixture screening by SPR, organometallic chemistry, photochemistry, electrochemistry, and 3D-printed custom labware including back-pressure regulators. Delivers scalable, reproducible synthetic chemistry for partner programmes.
• Vernalis KNIME Nodes (Open Source) Open-source KNIME community contribution providing workflow nodes for cheminformatics, structural informatics, data access, and general utility tasks. Includes PDB Connector, fingerprint manipulation, SMILES processing via Speedy SMILES nodes, Matched Molecular Pair Analysis (MMPA), and molecular property calculations. Released as a Trusted KNIME Community contribution; usable by the broader drug discovery community.

Quantifiable outcome

• Over 7000 crystal structures determined across more than 70 protein targets
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature9 records

Partnerships

Twelve partnerships are on record, tiered flagship, core and minor.

• LIGAND-AI Consortium (IHI Project)flagshipStrategic or Co-development Partner · 20 January 2026Vernalis joined the LIGAND-AI consortium, a multi-sector public-private partnership funded by the Innovative Health Initiative (IHI) with a budget exceeding €60 million. The five-year initiative brings together 18 partners across nine countries to generate large open datasets of protein-ligand interactions and train AI models capable of predicting molecular binding for thousands of human proteins. Led by Pfizer and the Structural Genomics Consortium (SGC), the project targets rare, neurological, and oncological conditions. All data will be shared according to FAIR principles.
• Structural Genomics Consortium (SGC)coreStrategic or Co-development Partner · 20 January 2026SGC is the project coordinator and co-leader of the LIGAND-AI consortium alongside Pfizer. SGC leads the open science ecosystem and coordinates data sharing according to FAIR principles across the 18 consortium partners.
• PfizercoreStrategic or Co-development Partner · 20 January 2026Pfizer co-leads the LIGAND-AI consortium alongside the Structural Genomics Consortium as a major pharmaceutical partner contributing to AI-driven drug discovery through open science.
• HitGen Inc.coreOthers · 20 January 2026Vernalis (R&D) Limited is a wholly owned subsidiary of HitGen Inc. (688222.SH). Vernalis is a member of the HitGen group of companies, which provides access to DNA Encoded Library (DEL) technology including PAC-FragmentDEL, OpenDEL, and DEL screening capabilities. HitGen is listed on the Shanghai Stock Exchange.
• Abcam LimitedminorStrategic or Co-development Partner · 20 January 2026Partner in the LIGAND-AI consortium. Abcam contributes recombinant protein engineering and production capabilities to generate high-quality binding datasets to support predictive model development.
• AstraZeneca UK LimitedminorStrategic or Co-development Partner · 20 January 2026Partner in the LIGAND-AI consortium, contributing to the public-private partnership for AI-driven drug discovery through open science.
• Novo NordiskminorStrategic or Co-development Partner · 20 January 2026Partner in the LIGAND-AI consortium, contributing to the public-private partnership for AI-driven drug discovery through open science.
• C4X DiscoverycoreStrategic or Co-development Partner · 8 April 2024Vernalis (R&D) Limited, a wholly owned subsidiary of HitGen Inc., entered a collaboration with C4X Discovery to identify modulators of an undisclosed high-value target involved in inflammatory disease. Vernalis uses its protein science and Hit ID platforms to produce the target protein and identify and characterise small molecule ligands. The research at Vernalis is funded by C4XD, with C4XD retaining ownership of resulting IP and having an option to extend the collaboration.
• ServiercoreStrategic or Co-development PartnerLong-standing collaboration partner in drug discovery programs, including work on Bcl-2 family proteins for cancer and DYRK1A kinase inhibitors. Vernalis and Servier have collaborated across multiple projects with integrated project teams.
• GenentechminorStrategic or Co-development PartnerPresent and past collaborator on challenging therapeutic targets as part of Vernalis's broad partnering network.
• LundbeckminorStrategic or Co-development PartnerPresent and past collaborator on challenging therapeutic targets as part of Vernalis's broad partnering network.
• Pierre FabreminorStrategic or Co-development PartnerPresent and past collaborator on challenging therapeutic targets as part of Vernalis's broad partnering network.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sygnature Discovery: UK-based CRO offering integrated drug discovery services from hit identification through pre-clinical candidates, with strength in medicinal chemistry, DMPK and in vitro pharmacology. Direct competitor for pharma outsourced discovery work, particularly on challenging targets.

Broad incumbents

• Evotec: Large global CRO offering end-to-end drug discovery and development services across multiple modalities and therapeutic areas. Competes for multi-target discovery collaborations with the same pharma clients as Vernalis, with broader scale but less specialisation in FBDD.
• Charles River Laboratories: Global CRO with extensive discovery, safety assessment and manufacturing services. Overlaps with Vernalis on early discovery and DMPK and competes for integrated discovery programs with large pharma, though most scale sits in later-stage and safety services.
• Pharmaron: China-headquartered CRO with integrated discovery, DMPK and manufacturing capabilities. Competes for outsourced discovery work globally, including structure-based and fragment-based approaches, often at lower price points.
• WuXi AppTec: Large China-based CRO/CDMO with extensive discovery, preclinical and manufacturing services. Competes globally for outsourced discovery work, including with China-based biotech clients, with materially larger scale than Vernalis.
• Eurofins Discovery: Global CRO providing drug discovery, in vitro pharmacology and ADME services through the former Eurofins Pharma Discovery and acquired capabilities. Overlaps with Vernalis on assay development, biophysics and DMPK contracts from pharma and biotech.

Emerging players

• HitGen: Parent company of Vernalis, listed on the Shanghai Stock Exchange, focused on DNA Encoded Library (DEL) technology including OpenDEL and PAC-FragmentDEL. Sister-company relationship creates both synergy and potential channel conflict for Vernalis's UK-based fragment and SBDD services.
• Schrödinger: Computational drug discovery platform combining physics-based modelling with collaborative discovery services. Competes for early-stage discovery budgets from pharma, increasingly on AI-enabled hit identification that overlaps with Vernalis's structural biology work.
• Exscientia: AI-native drug discovery company offering end-to-end discovery partnerships with pharma. Represents a new entrant competing for the same pharma discovery spend, particularly as AI-driven design becomes more credible.
• C4X Discovery: UK-based drug discovery company using its Conformetrix and other proprietary chemistry platforms. A current Vernalis partner (April 2024 inflammatory disease collaboration), illustrating the biotech client segment Vernalis serves; also a potential competitor for discovery work with biotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• GitHubgithub.com/vernalis
• LinkedInlinkedin.com/company/vernalis

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vernalis